Mangrove Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Mangrove Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-36,413	Closed	-$8.89M	–	125
2020 Q3	$8.89M	Buy	36,413 +4,818	+15%	+$1.5M	1.12%	27
2020 Q2	$9.1M	Buy	31,595 +8,801	+39%	+$2.59M	2.22%	14
2020 Q1	$4.65M	Sell	22,794 -5,449	-19%	-$1.74M	0.64%	29
2019 Q4	$12.6M	Hold	28,243	–	–	1.85%	18
2019 Q3	$8.69M	Hold	28,243	–	–	1.05%	23
2019 Q2	$8.98M	Buy	28,243 +10,000	+55%	+$3.46M	1.02%	26
2019 Q1	$7.65M	Hold	18,243	–	–	1.02%	24
2018 Q4	$5.56M	Buy	+18,243	New	+$5.89M	0.74%	30
2015 Q2	–	Sell	-2,222	Closed	-$18.9M	–	44
2015 Q1	$18.9M	Buy	+2,222	New	+$19.4M	4.57%	5

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mangrove Partners's EIGR Position: Q4 2020 in Review

Mangrove Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 36,413 shares — an estimated $8.89M sold.

Mangrove Partners first reported a position in EIGR in Q1 2015 and held it in 9 quarters. The position peaked at $18.9M in Q1 2015. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Mangrove Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Mangrove Partners sold 36,413 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $8.89M.
Mangrove Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 9 quarters.
Mangrove Partners's Eiger BioPharmaceuticals, Inc. position peaked at $18.9M in Q1 2015.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Mangrove Partners's 13F filing for Q4 2020, filed 16 Feb 2021.